RECAF (Cancer vs normals) ** 90% 100% RECAF (Cancer vs benign) *** 88% 100%
Yes, I have read that older data and hose are great results. Why have the lastest two press releases on prostate cancer not reflected those same great results?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.